June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Longterm effect of multiple intravitreal anti VEGF injection on intraocular pressure
Author Affiliations & Notes
  • Yoon Jeon Kim
    Asan Medical Center, Seoul, Republic of Korea
  • Kyung Rim Sung
    Asan Medical Center, Seoul, Republic of Korea
  • Yoo-Ri Chung
    Asan Medical Center, Seoul, Republic of Korea
  • Kyoung Sub Lee
    Asan Medical Center, Seoul, Republic of Korea
  • Soo Geun Joe
    Asan Medical Center, Seoul, Republic of Korea
  • Joo Yong Lee
    Asan Medical Center, Seoul, Republic of Korea
  • June-Gone Kim
    Asan Medical Center, Seoul, Republic of Korea
  • Young Hee Yoon
    Asan Medical Center, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships Yoon Jeon Kim, None; Kyung Rim Sung, None; Yoo-Ri Chung, None; Kyoung Sub Lee, None; Soo Geun Joe, None; Joo Yong Lee, None; June-Gone Kim, None; Young Hee Yoon, Allergan (R), Bayer (C), Alcon (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 6301. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yoon Jeon Kim, Kyung Rim Sung, Yoo-Ri Chung, Kyoung Sub Lee, Soo Geun Joe, Joo Yong Lee, June-Gone Kim, Young Hee Yoon; Longterm effect of multiple intravitreal anti VEGF injection on intraocular pressure. Invest. Ophthalmol. Vis. Sci. 2013;54(15):6301.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate the longterm effect of multiple intravitreal anti-vascular endothelial growth factor (VEGF) injections on intraocular pressure (IOP) in eyes with neovascular age related macular degeneration (AMD) and retinal vein occlusion (RVO).

 
Methods
 

Patients who underwent multiple (more than 3 times) intravitreal anti-VEGF injections and were followed more than 12 months after last injection were consecutively enrolled. Clinical information such as baseline demographics, underlying disease, baseline IOP, and frequency of anti-VEGF injections were obtained via medical record review. IOP elevation was defined as increase of 5mmHg higher than baseline measurement on 2 consecutive visits. The frequency of IOP elevation was determined, and hazard ratio of each putative risk factor for IOP elevation was calculated using Cox proportional hazard model.

 
Results
 

Six hundred and thirty nine eyes with neovascular AMD and 95 eyes with RVO were included in the analysis. Twenty eyes with neovascular AMD (3.0%) and 7 eyes with RVO (7.4%), showed IOP elevation after multiple anti-VEGF injections. In 27 eyes experiencing IOP elevation, IOP at the last follow up was 13.9 ± 2.3 mmHg, which was not significantly different from the baseline IOP, 13.4 ± 3.0 mmHg (P = 0.53). In neovascular AMD patients, history of IOP elevation associated with intravitreal steroid injections (34.465, P = 0.002), and history of glaucoma (4.201, P = 0.0285) were significant risk factors according to multivariate Cox proportional hazards. In RVO patients, history of glaucoma (7.217, P= 0.047) was a significant risk factors. In cox proportional hazard analysis of total participants incorporating underline disease as another variable, history of IOP elevation associated with intravitreal steroid injections (25.154, P = 0.002), history of glaucoma (5.294, P = 0.003), baseline IOP of treated eyes (0.826, P = 0.009), and diagnosis of RVO (2.959, P = 0.019) were significant risk factors for IOP elevation after multiple anti-VEGF injections.

 
Conclusions
 

The incidence of IOP elevation after multiple intravitreal anti-VEGF injections was low, and elevated IOP was normalized without medication in most of cases in our study.

 
Keywords: 568 intraocular pressure • 503 drug toxicity/drug effects • 748 vascular endothelial growth factor  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×